Targeting T cells to tumor cells using bispecific antibodies
- 30 June 2013
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Chemical Biology
- Vol. 17 (3), 385-392
- https://doi.org/10.1016/j.cbpa.2013.03.029
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLBlood, 2012
- Blinatumomab: A historical perspectivePharmacology & Therapeutics, 2012
- Immunology beats cancer: a blueprint for successful translationNature Immunology, 2012
- Advances in the development of cancer immunotherapiesTrends in Immunology, 2012
- What are regulatory T cells (Treg) regulating in cancer and why?Seminars in Cancer Biology, 2012
- The immune contexture in human tumours: impact on clinical outcomeNature Reviews Cancer, 2012
- Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell LymphomaBlood, 2011
- Tumor‐dependent down‐regulation of the ζ‐chain in T‐cells is detectable in early breast cancer and correlates with immune cell functionInternational Journal of Cancer, 2011
- Improving cancer immunotherapy by targeting tumor-induced immune suppressionCancer and Metastasis Reviews, 2011
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging AntibodyScience, 2008